ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative) - USD ($) |
Jun. 11, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|---|---|---|---|
| Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | |
| Asset Purchase Agreement [Member] | Trigemina, Inc.[Member] | |||
| Payment for purchase of assets | $ 824,759 | ||
| Number of shares issued (in shares) | 2,000,000 | ||
| Common stock, par value (in dollars per share) | $ 0.001 | ||
| Common stock value (per share) | $ 0.68 | ||
| Research and development costs | $ 2,400,000 | ||
| Assignment and Assumption Agreement [Member] | |||
| Payment for purchase of assets | $ 250,241 |
| X | ||||||||||
- Definition Common stock value per share. No definition available.
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|